Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinotic is a branded non‑antibiotic otic solution containing chloroxylenol, pramoxine hydrochloride, and zinc acetate, used primarily for the treatment of acute otitis externa and other superficial infections of the external ear. Chloroxylenol is a halogenated phenolic antiseptic with broad‑spectrum bactericidal and antifungal activity that treats the underlying infection, while pramoxine is a topical anesthetic that stabilizes neuronal membranes to provide rapid relief of ear pain and pruritus, and zinc acetate acts as a skin protectant that helps restore and shield the damaged epithelium of the ear canal.[1][3][7][9] This combination, developed and marketed by Arbor Pharmaceuticals as part of a pediatric‑focused ear‑care franchise, is administered as ear drops and is intended to simultaneously control infection, alleviate symptoms, and support healing of the ear canal without the use of systemic or topical antibiotics.[3][7][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zinotic.